Ciclosporine et psoriasis grave

Annales de Dermatologie et de Venereologie

Volumn 123, Issue 4, 1996, Pages 280-284

  Mazer, J M ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

ARTICLE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; PSORIASIS; SIDE EFFECT;

CYCLOSPORINE; DRUG INTERACTIONS; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; PSORIASIS;

EID: 0030001503     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Mueller W, Hermann B. Cyclosporin A for psoriasis. N Engl J Med 1979;301:555.
2. Van Hoof JP, Levissen K. Cyclosporin and psoriasis. Lancet 1985;i:335-9.
3. Marks JM. Low dose Cyclosporin A in severe psoriasis: a double blind study. Transplant Proc 1988;20(suppl 4):68-71.
4. Marks JM. Cyclosporin A treatment of severe psoriasis. Br J Dermatol 1986;115:745-6.
5. Van Joost T, Heule F, Stolz E, Beukers R. Short term use of Cyclosporin A in severe psoriasis. Br J Dermatol 1986;114:615-20.
6. Borel JF. Mechanism of action and rationale for Cyclosporin A in psoriasis. Br J Dermatol 1990;122(suppl 36):5-12.
7. Gerritsen MJ, Rulo JHF, Arnold WP, Van de Kerkhof PC. Response of clinically uninvolved skin of psoriasis patients to repeated tape stripping during cyclospsorin A treatment. Br J Dermatol 1994;130:191-8.
8. Kanitakis J, Urabe A, Haftek M, Thivolet J. The effects of cyclosporin A in proliferation and differentiation associated antigens of normal human skin xenograf Red into nude mice. J Dermatol Sci 1990;1:103-10.
9. Christophers E, Mrowietz V, Henneicke HH. Cyclosporin in psoriasis: a multicenter dose finding study in severe plaque psoriasis. J Am Acad Dermatol 1992;26:86-90.
10. Laburte C, Grossman R, Abirached J, Abeywickrama K, Dubertret L. Efficacy and safety of oral cyclosporin A (Sandimum®) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994;130:366-75.
11. Youn J, Moon S, Kim D, Parek E, Moon D, Kim K et al. Cyclosporin treatment of psoriasis. J Dermatol Treatment 1993; 4:123-6.
12. Timonen P, Friend D, Abeywikrama K. Efficacy of low dose cyclosporin in psoriasis. Br J Dermatol 1990;122(suppl 36):33-9.
13. Brown A, Wilkinson R, Thomas T, Levell N, Mumo C, Marks J et al. The effect of short term low dose cyclosporin on renal function and blood pressure in patients with psoriasis. Br J Dermatol 1993;128:550-5.
14. Niaudet P. La néphrotoxicité de la cyclosporine est-elle inéluctable? Presse Méd 1994;23:1061-64.
15. Powles A, Cook T, Hulme B, Baber B, Lewis H, Thomas E et al. Renal function and biopsy finding after 5-year's treatment with low-dose cyclosporin for psoriasis. Br J Dermatol 1993;128: 159-65.
16. Mason J. Renal side effects of cyclosporin A. Br J Dermatol 1990;122(suppl 36):71-7.
17. Feutren G, Mihattsch M. Risk factors for cyclosporin induced nephropathy in patients with auto-immune diseases. N Engl J Med 1992;326:1654-60.
18. Feutren G, Abeywickrama K, Friend D, Von Graffenreid B. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol 1990;122(suppl 36):57-69.
19. Green C, Hawk JL. Cutaneous malignancy relates to cyclosporin A therapy. Clin Exp Dermatol 1993;18:30-1.
20. Stern RS. Risk assessment of PUVA and cyclosporin. Arch Dermatol 1989;125:545-7.
21. Penn I. Cancers following cyclosporin therapy. Transplantation 1987;43:32-5.